Capital Fund Management (CFM)
TVTX icon

Capital Fund Management (CFM)’s Travere Therapeutics TVTX Stock Holding History

Capital Fund Management (CFM)’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-85,881
Closed -$2.55M – 2396
2026
Q1 		$2.55M Buy
+85,881
New +$2.57M 0.01% 1242
2025
Q4 		– Sell
-41,512
Closed -$992K – 2675
2025
Q3 		$992K Sell
41,512
-59,894
-59% -$1.13M ﹤0.01% 2106
2025
Q2 		$1.5M Buy
+101,406
New +$1.68M ﹤0.01% 1824
2023
Q3 		– Sell
-43,824
Closed -$673K – 2098
2023
Q2 		$673K Buy
+43,824
New +$797K ﹤0.01% 1512

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Fund Management (CFM)'s TVTX Position: Q2 2026 in Review

Capital Fund Management (CFM) sold out of Travere Therapeutics (TVTX) in Q2 2026, closing a stake of 85,881 shares — an estimated $2.55M sold.

Capital Fund Management (CFM) first reported a position in TVTX in Q2 2023 and held it in 4 quarters. The position peaked at $2.55M in Q1 2026. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Capital Fund Management (CFM) reported no remaining Travere Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 85,881 Travere Therapeutics shares in Q2 2026, an estimated $2.55M.
  • Capital Fund Management (CFM) first reported a position in Travere Therapeutics in Q2 2023 and held it in 4 quarters.
  • Capital Fund Management (CFM)'s Travere Therapeutics position peaked at $2.55M in Q1 2026.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2026, filed 13 Aug 2026.